IBA showcases low-cost proton therapy
Belgium-based IBA (Ion Beam Applications) is hawking its two-room proton therapy solution this week at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting as a smaller, lower-cost alternative to traditional proton therapy centers.
Belgium-based IBA (Ion Beam Applications) is hawking its two-room proton therapy solution this week at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting as a smaller, lower-cost alternative to traditional proton therapy centers. The IBA configuration, dubbed Proteus Nano, starkly contrasts the often two-story proton therapy centers that occupy as much as 100,000 square feet. The company is framing Proteus Nano as requiring a much smaller footprint and imposing a lower acquisition cost, while still providing the highly accelerated proton beams needed to kill cancer tumors.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
